8-K: Niagen Bioscience Reports Q3 2026 Results, Launches New Products
Quarterly Earnings Results
Niagen Bioscience announced third quarter 2026 financial results, highlighting net sales of $27.2 million and positive Adjusted EBITDA, alongside strategic product launches and clinical trial advancements.
Summary
- Niagen Bioscience reported net sales of $27.2 million for the third quarter of 2026, with $23.3 million attributed to Tru Niagen.
- The company generated $2.6 million in operating cash flow for the three-month period and ended the quarter with $69.5 million in cash and cash equivalents.
- Key product launches included Niagen Plus At-Home Injections, Niagen NanoCloud topical product, and the 'Don't Get Old. Age Better.' brand campaign.
- Strategic advancements include a Start-Up Agreement with Mass General Brigham for a large clinical trial and engagement of Red Sky Partners for the NB4168 drug candidate.
- The company reported a net loss of $1.2 million, or $(0.01) per share, but achieved positive Adjusted EBITDA of $0.5 million.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive report, with strategic investments and new product launches offsetting a slight net loss and acknowledging near-term commercial headwinds.
Positives
- Direct to consumer sales on the company's website grew by 13% year-over-year.
- Gross margin remained strong at 62.9%.
- Achieved positive Adjusted EBITDA of $0.5 million.
- Generated $2.6 million in operating cash flow for the quarter.
- Ended the quarter with $69.5 million in cash and cash equivalents, an increase from the previous quarter.
- Launched new product lines: Niagen Plus At-Home Injections and Niagen NanoCloud skincare.
- Initiated a significant clinical trial planning with Mass General Brigham.
- Expanded e-commerce presence with Walmart.com and retail footprint with GNC and Sam's Club.
Negatives
- Reported a net loss of $1.2 million for the third quarter of 2026.
- Net sales decreased to $27.2 million from $33.9 million in the same quarter of the previous year.
- The ingredient business is expected to be lower than the prior year due to competitive market dynamics.
- Operating expenses are expected to increase due to strategic investments.
Risks
- Competitive market dynamics impacting the ingredient business.
- Potential for decreased demand for products and services.
- Market acceptance of new products.
- Interruptions in sales through third-party online marketplaces.
- Ability to protect intellectual property rights.
- Impact of litigation or infringement actions.
- Regulatory scrutiny of advertising, marketing, and sales practices.
- Competition from other providers and products, including NMN.
Future Outlook
For the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year. The ingredient business is expected to be lower than the prior year. Niagen Plus growth and new skincare partnerships are expected to become meaningful contributors beginning in 2027. Operating expenses are expected to increase due to strategic investments.
Management Comments
- "During the third quarter, we navigated near-term commercial headwinds while continuing to generate positive adjusted EBITDA and $2.6 million in operating cash flow and make tangible progress across the Niagen platform."
- "We advanced NB4168, expanded Tru Niagen distribution, established skincare as a permanent category, launched a more convenient ready-to-inject Niagen Plus product, and invested in brand awareness and long-term clinical research."
- "As stated before, we view 2026 as an investment year, and believe the progress we are making across consumer health, ingredients, injectables, skincare, and pharmaceuticals provides a strong springboard for meaningful growth in 2027 and beyond."
Industry Context
StockSavvy.ai notes that Niagen Bioscience is operating in the growing healthy aging and NAD+ supplement market. The company's diversification into injectables, skincare, and pharmaceutical development reflects broader industry trends of expanding product applications and targeting specific health concerns beyond traditional supplements.
Comparison to Industry Standards
- The company's gross margin of 62.9% appears strong within the supplement and health products industry, though direct comparisons require specific competitor data.
- The net loss of $1.2 million, while a negative, is common for companies investing heavily in R&D and market expansion, a strategy seen in many biotech and health science firms.
- The focus on NAD+ precursors places Niagen Bioscience in a niche but rapidly developing segment of the health and wellness market, with ongoing research into its benefits for aging and various health conditions.
Stakeholder Impact
- Shareholders: The company's investment strategy may impact short-term profitability but aims for long-term growth, potentially increasing shareholder value.
- Employees: Increased operating expenses suggest continued investment in personnel and operations.
- Customers: New product launches (Niagen Plus injections, NanoCloud skincare) and expanded retail presence (Walmart, GNC, Sam's Club) offer more options and accessibility.
- Partners: The company continues to engage with ingredient partners and is adding new ones, while also advancing pharmaceutical partnerships.
Next Steps
- Continue investment in commercial, research, and administrative functions.
- Focus on disciplined capital allocation and positive cash flow from operations.
- Niagen Plus growth and new skincare partnerships expected to become meaningful contributors in 2027.
- Advance NB4168 drug candidate with support from Red Sky Partners.
- Begin detailed planning for a large clinical trial of Niagen with Mass General Brigham.
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | End of third quarter 2026 |
| 2026-11-04 | Date of report and earnings release for Q3 2026 |
Recommendation
holdThe company is in a period of strategic investment, showing positive operational cash flow and Adjusted EBITDA despite a net loss. New product launches and clinical advancements are promising, but the ingredient business faces headwinds and overall sales declined year-over-year. A 'hold' recommendation reflects the balance between ongoing investment and current performance challenges, awaiting clearer signs of sustained growth and profitability in 2027.
Keywords
NAD+, Niagen, Tru Niagen, Healthy Aging, Nicotinamide Riboside, NB4168, Clinical Trial, Nutraceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.